Vistagen Therapeutics, Inc. Nasdaq Delisting Warning: What Investors Need to Know

---

Vistagen Therapeutics Faces Nasdaq Delisting Warning: What Investors Need to Know

Vistagen Therapeutics, a clinical-stage biopharmaceutical company developing treatments for anxiety, depression, and other central nervous system (CNS) disorders, recently received a critical warning from Nasdaq. This notice signals potential delisting and carries significant implications for investors.

Event Description

Nasdaq recently notified Vistagen Therapeutics, which trades on the Nasdaq Capital Market, that it no longer meets the exchange's minimum bid price requirement. Vistagen's common stock traded below $1.00 per share for 30 consecutive business days, triggering this non-compliance warning.

Event Date/Timeline

Nasdaq issued the official notice on February 3, 2026.

Vistagen now faces a clear timeline to resolve this issue:

• Initial Compliance Period: Vistagen has 180 calendar days from February 3, 2026, until August 3, 2026, to regain compliance.
• Requirement: To do so, its common stock's closing bid price must be $1.00 or higher for at least 10 consecutive business days during this period.
• Potential Extension: If Vistagen does not meet this initial deadline but satisfies other Nasdaq listing criteria (like market value of publicly held shares and stockholders' equity), it may qualify for an additional 180-day compliance period.
• Company's Plan: Vistagen announced it will actively monitor its stock price and explore all options to regain compliance. These options may include a reverse stock split, strategic financing, or accelerating key clinical milestones to generate positive news.

Impact Assessment

This warning is more than a technicality; it's a significant event with serious implications. Nasdaq's $1.00 minimum bid price rule ensures listed companies maintain market value and investor interest. Vistagen's prolonged trading below this threshold suggests investors harbor concerns about its financial health, clinical pipeline progress, or market strategy.

The most immediate risk is delisting from the Nasdaq Capital Market. If Vistagen fails to regain compliance, Nasdaq could remove its shares from this major exchange, potentially relegating them to the over-the-counter (OTC) markets. Delisting would:

• Reduce Liquidity: Investors would find it harder to buy and sell shares quickly and at fair prices.
• Limit Institutional Investment: Many institutional investors cannot invest in OTC stocks, further reducing demand.
• Damage Reputation & Future Funding: Delisting severely harms a company's credibility, making it more challenging to attract new investors, secure partnerships, or raise capital for its critical drug development programs.

Financial Impact

While the Nasdaq non-compliance notice does not immediately affect Vistagen's current business operations, SEC reporting requirements, or the validity of its common stock, the company continues to operate as usual. However, failure to regain compliance could lead to delisting, which would have significant financial repercussions, including reduced access to capital markets and limitations on institutional investment. Vistagen has not disclosed any immediate financial covenants triggered by this notice.

Key Takeaways for Investors

For Vistagen shareholders, this notice signals a period of heightened uncertainty and potential volatility:

• Monitor Closely: Watch the stock's daily closing bid price against the $1.00 threshold.
• Strategic Actions: Be aware that Vistagen may pursue a reverse stock split. While this artificially boosts the share price to meet Nasdaq requirements, it does not change the company's overall market capitalization or underlying value. Investors often view it as a sign of distress, and it can sometimes lead to further price depreciation post-split.
• Underlying Business Performance: The most sustainable way for Vistagen to regain and maintain compliance is through positive developments in its clinical pipeline (e.g., successful trial results for lead candidates like PH94B or PH10), securing new partnerships, or demonstrating a clear path to commercialization and profitability. Investors should look for concrete updates on these fronts.
• Liquidity Risk: Understand that prolonged non-compliance and potential delisting could significantly impair your ability to easily trade Vistagen shares.
• Re-evaluate Investment Thesis: This situation warrants a re-evaluation of your original investment reasons. Consider how the delisting risk and the company's proposed strategies align with your long-term outlook for Vistagen's drug development programs and financial viability.